On 4 February the Gabinete Técnico Farmacéutico M. Camps and consultancy Azierta organise the webinar "Vigilance and post-marketing of medical devices".
This training, which will be held online for registered users -attendance is free of charge, subject to registration- will provide an overview of regulation and the steps to be taken to carry out PS monitoring.
The market surveillance and monitoring are an essential part of the marketing of medical devices.This is a sector in continuous innovation and of great importance in the European and Spanish market.
The webinar will be moderated by:
- Mercè Camps. CEO and founder of the Technical Pharmaceutical Cabinet MCamps
- Olegario Cuevas. Healthcare Business Manager at Azierta
The webinar presentation will be conducted by:
- Silvia de Andrés. Medical Devices Officer
- Alberto Orós. Technical Consultant
Surveillance and marketing of medical devices:
webinar programme
-
-
- Introduction
- Surveillance system
- Incident management
- Security corrective actions (FSCA) and security notices (FSN)
- Trend reporting
- Post-market surveillance system
- Periodic Security Update Report (PSUR)
- Post Market Monitoring Report (PMSR)
- Post-marketing clinical follow-up
-
Latest articles in our blog
European Commission presents 2015 report on RAPEX alerts
On 25 April, Vera Jourova, the European Commissioner for Justice and Consumers, presented a 2015 review of the European Rapid Alert System (RAPEX), a platform set up by the European Commission in 2003 to inform citizens of the latest developments in the...
Rapex report 29-4-2016: quiet week for cosmetics
In the Rapex alert of Friday 29 April, 30 products were recalled in the European market. In Spain, the bans covered 7 articles: a car of Polish origin, and 5 toys and a costume from China. Regarding the cosmetics sector, we have...
AEMPS presents its new 2016-2019 plan against counterfeit medicines
On 11 April, the AEMPS presented its document Strategy against falsified medicinal products 2016-2019. It provides an introduction to Directive 2011/62/EU, the Community code to prevent the entry of falsified medicinal products into the supply chain.